A Phase II, Multicenter, Open-label, Randomized Two-year Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 10 Nov 2019 Planned End Date changed from 10 Mar 2022 to 28 Feb 2023.
- 10 Nov 2019 Planned primary completion date changed from 10 Mar 2022 to 21 Apr 2022.
- 15 Mar 2019 This trial was discontinued in Germany, according to European Clinical Trials Database.